Social post details patch killing 97% of cancer cells

American Chemical Society materials published on April 1 described a stretchable, heat-activated skin patch for melanoma, and an X post on May 17 recirculated the work with the claim that it kills 97% of cancer cells. The underlying research was published in ACS Nano on March 5, 2026, according to the paper in PubMed Central. The study did not report human testing. The reported 97% figure came from a 10-day mouse study of melanoma lesions, not a clinical trial in patients. ### Where did the “97%” claim come from? The ACS press summary said the treatment “reduced melanoma lesions by 97%” in mice after researchers activated the patch with a low-power laser on days 1 and 5 of a 10-day study. The same summary said the patch also killed “most” cultured melanoma cells in laboratory testing. (acs.org) The paper’s abstract described “effective tumor suppression within 10 days” in a mouse model after two one-hour phototherapy sessions, but the social-media framing compressed several results into a single headline number. The study focused on melanoma, a skin cancer, rather than cancer broadly. ### What is this patch actually made of? The ACS materials said the device is a soft, stretchable patch built from laser-induced graphene loaded with copper oxide and embedded in a silicone polymer. (acs.org) The researchers said the patch is breathable, chemically inert before activation and designed to sit on the skin over a tumor. (pmc.ncbi.nlm.nih.gov) The named authors on the paper were Xiaoyu Xu, Le Cheng, Baoping Li, Xinyu Wang, Siyu Chen, Zihao Li, Li Zhou, Tengyue Liu, Yidan Zhou, Zhiqiang Li, Xin Li, Shi Chen, Meijia Gu and Ruquan Ye. ### How does the treatment work? The researchers said a low-power laser warmed the patch to 108 degrees Fahrenheit, or 42 degrees Celsius. That heating triggered release of copper ions into melanoma cells beneath the patch, according to the ACS summary. (acs.org) The paper said the treatment increased reactive oxygen species and induced several cell-death pathways, including apoptosis, cuproptosis and ferroptosis. (pmc.ncbi.nlm.nih.gov) The authors also wrote that the patch inhibited tumor invasion and metastasis and boosted antitumor immunity in the mouse model. ### Did the study show it leaves healthy tissue unharmed? The ACS press summary said the mouse tests reduced melanoma lesions “without damaging surrounding tissue.” It also said tissue samples showed cancer cells had not migrated beyond tumor borders and that copper ions had not accumulated in organs or blood in the early animal study. (acs.org) (pmc.ncbi.nlm.nih.gov) The paper described the patch as biocompatible and said its design was intended to minimize toxic side effects. But those findings came from preclinical work in cultured cells and mice, not from long-term safety data in people. ### Does this mean surgery for melanoma is about to be replaced? The paper said surgical excision remains the standard treatment for melanoma. (acs.org) The ACS summary said the patch “could someday” become part of a noninvasive treatment, which is a forward-looking statement rather than evidence of current medical use. (pmc.ncbi.nlm.nih.gov) No source reviewed here reported an approved human trial, regulatory clearance or a commercial product. The work is best described as early-stage preclinical research on a possible noninvasive melanoma treatment. ### What can readers check next? The March 5, 2026 ACS Nano paper, DOI 10.1021/acsnano.5c21102, is the primary source for the study details, and the American Chemical Society’s April 1, 2026 press summary gives the mouse-study result cited in social posts. (acs.org) Any next step to watch would be a named human clinical trial from the research team or an institutional announcement tied to those authors.